Table 2 Level of circulating microparticles (MPs), secretory phospholipase A2 (sPLA2), sCD40L, sCD62P in patients with primary Sjögren syndrome (pSS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and in healthy controls (HCs)
pSS | SLE | RA | HC | ||
|---|---|---|---|---|---|
MP level by capture assay, nM PS Eq | Total MPs (n) | 8.49 ± 1.14 (43) | 7.3 ± 1.25 (20) | 7.23 ± 1.05 (26) | 4.13 ± 0.2 (44) |
Platelet GPIb+ MPs (n) | 4.89 ± 1.25 (40) | 4.28 ± 0.36 (18) | 4.86 ± 1.48 (24) | 1.12 ± 0.11 (18) | |
Leukocyte CD11a+ MPs (n) | 5.78 ± 0.37 (40) | 3.89 ± 0.4 (17) | 4.28 ± 0.9 (21) | 3.92 ± 0.21 (44) | |
MP number/μL plasma by FACS | Total MPs (n) | 91,700 ± 31,292 (5) | 71,230 ± 19,160 (4) | 127,200 ± 46,825 (2) | 6422 ± 3472 (5) |
Platelet CD61+ MPs (n) | 48,930 ± 18,260 (4) | 32,290 ± 17,250 (4) | 94370 ± 46,584 (2) | 4229 ± 3914 (4) | |
Leukocyte CD45+ MPs (n) | 927 ± 729 (4) | 422 ± 149 (4) | 304 ± 33 (2) | 190 ± 100 (4) | |
sPLA2 activity, nmol/min/mL (n) | 50.9 ± 3.5 (37) | 60.7 ± 8.0 (17) | 69.8 ± 9.3 (25) | 41.8 ± 3.4 (28) | |
sCD40L, pg/mL (n) | 233 ± 31.7 (33) | 262.6 ± 63.9 (17) | 345.7 ± 67.23 (25) | 133.6 ± 4.8 (33) | |
sCD62P, ng/mL (n) | 38.9 ± 2.5 (34) | 39.3 ± 3.7 (16) | 43.4 ± 3.0 (25) | 23.0 ± 1.0 (32) | |